| Name | Title | Contact Details |
|---|
MedLite ID is an easy-to-use, disposable medical device that enables clinicans to accurately and efficiently identify a single medication infusion line against similar infusion lines in any light setting. The ninth leading cause of medical-error deaths in the United States involves infusion line confusion, and nearly 65 percent of those cases are related to the medication infusion line. MedLite ID eliminates infusion confusion by providing indicators with built-in wireless light technology at the medication bag, connector, and to patient. Each MedLite ID device is unique to its individual medication infusion line and cuts the process of infusion line identification to mere seconds. This saves clinicians precious time while also drastically mitigating risk and reducing stress while ensuring better care and patient outcomes.
Tesseract Health is part of the 4Catalyzer accelerator, with over $700 Million in funding, 300 scientists and engineers. Our offices are in Guilford CT, New York City, and Palo Alto.
We are one of the world`s leading suppliers of processing solutions to the ophthalmic and precision-optical industry. SCHNEIDER innovations set the pace – in freeform generating and polishing of eye glasses, in grinding and polishing of precision aspheres, and in process metrology. We set technical standards and open up new and more productive solutions to our customers. We are distinctive for our development of new technologies and swift translation of technological concepts into customer-oriented innovations.
Vestergaard Frandsen is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 1993, a novel technology was invented by a team that included Jon Faiz Kayyem, PhD at The California Institute of Technology (CalTech). This invention combined nucleic acids and microelectronics to produce an electronic sensor for DNA detection. His invention was based on electrical detection of nucleic acids on a cassette based detection platform. Dr. Kayyem went on to found Clinical Micro Sensors, with the goal of translating this “eSensor” technology to disposable chips. Following several acquisitions of the technology, Dr. Kayyem became actively involved again in 2009, returning as an investor and then as CEO and Chairman of the Board. In 2009, a collaboration between Dr. Kayyem and Christopher Gleeson began. The two redefined the company strategy, and brought in a new board of directors, executive leadership team, and commercial management. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. Mr. Gleeson remained an integral part of GenMark`s growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. Dr. Kayyem currently serves as SVP, Research and Development.